The U.S. Food and Drug Administration (FDA) today approved an imaging drug known as Cytalux (pafolacianine), which is attracted to ovarian cancer tissue and illuminates it when exposed to fluorescent light, allowing surgeons to more easily find and more precisely remove the cancer. Physicians at the Center for Precision Surgery in the Abramson Cancer Center at the University of Pennsylvania led one of the largest clinical trial site in the country for the drug, in a partnership with the Indiana-based On Target Laboratories. The approach brings fresh hope to patients diagnosed with ovarian cancer, about half of whom experience a recurrence of their disease after initial treatment. Penn investigators have pioneered targeted technologies for lung, brain, and urinary tract cancers.
Original Article: medicalxpress.com